TP10: Phase I/II

In AVAN's open label Phase I/II trial of 15 infants undergoing cardiac surgery, no deaths occurred and no adverse events were attributed to TP10. The product decreased abnormal vascular permeability and pulmonary dysfunction following cardiopulmonary bypass, however the researchers suggested that an optimal dosing strategy should be defined as TP10 levels were lower in neonates despite receiving the same weight-adjusted dose as older infants. Data were presented at the American Heart Association meeting in New Orleans. ...